A modified HSP70 inhibitor shows broad activity as an anticancer agent.
about
Crystal structure of the stress-inducible human heat shock protein 70 substrate-binding domain in complex with peptide substrateThe G protein α chaperone Ric-8 as a potential therapeutic targetFunctional analysis of Hsp70 inhibitorsThe human HSP70 family of chaperones: where do we stand?Structural basis for the inhibition of HSP70 and DnaK chaperones by small-molecule targeting of a C-terminal allosteric pocketProtein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugateEvaluating melanoma drug response and therapeutic escape with quantitative proteomicsProtein chaperones: a composition of matter review (2008 - 2013).Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic fluxHsp72 is targeted to the mitotic spindle by Nek6 to promote K-fiber assembly and mitotic progression.Quantitative proteomics of the yeast Hsp70/Hsp90 interactomes during DNA damage reveal chaperone-dependent regulation of ribonucleotide reductase.Hsc70 chaperone activity underlies Trio GEF function in axon growth and guidance induced by netrin-1.Mutations in the Yeast Hsp70, Ssa1, at P417 Alter ATP Cycling, Interdomain Coupling, and Specific Chaperone Functions.Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease.The HSP70 family and cancerHSP70 inhibition by 2-phenylethynesulfonamide induces lysosomal cathepsin D release and immunogenic cell death in primary effusion lymphoma.HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.Heat shock proteins regulate activation-induced proteasomal degradation of the mature phosphorylated form of protein kinase C.Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and HSP90 inhibition.Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?Hsp70 in cancer: back to the future.Targeting Hsp70: A possible therapy for cancer.Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function.Targeting Allosteric Control Mechanisms in Heat Shock Protein 70 (Hsp70).Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer.Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma.Exogenously delivered heat shock protein 70 displaces its endogenous analogue and sensitizes cancer cells to lymphocytes-mediated cytotoxicity.Pifithrin-μ, an inhibitor of heat-shock protein 70, can increase the antitumor effects of hyperthermia against human prostate cancer cells.Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic ApproachEtoposide induces cell death via mitochondrial-dependent actions of p53.Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents.Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer.Hsp70: A Cancer Target Inside and Outside the Cell.N-Acetyl-l-Cysteine Protects Astrocytes against Proteotoxicity without Recourse to Glutathione.Domain Mapping of Heat Shock Protein 70 Reveals That Glutamic Acid 446 and Arginine 447 Are Critical for Regulating Superoxide Dismutase 2 Function.The Hsp70 inhibitor 2-phenylethynesulfonamide inhibits replication and carcinogenicity of Epstein-Barr virus by inhibiting the molecular chaperone function of Hsp70
P2860
Q21090602-8205B4CB-3237-4E8D-A4B1-6B0C90D0E830Q26824363-B8905005-E883-430A-B0BC-12020B1A3993Q27680671-BC32628E-0020-4DDF-B4E4-B20AED1C03BBQ28071416-AD109330-2161-47CC-8D6C-11C9A73E0B75Q28246523-EAA94E1D-71D1-4D95-B544-BCC1593E74CCQ28537657-D130C57F-F55E-47EC-B383-F2A16A1DEDE2Q33850665-84126965-6600-4827-98BD-9AA45E99CC69Q34013266-9EDF2EE2-4B7B-45E9-A463-4D4B03102D60Q35057071-CC9ED2F6-00D3-4621-A1F8-1A73DB5E42FFQ35594561-F1261421-CFC2-4CE6-8817-1FA6A7C4AC8BQ35799982-AD670AF0-6C8E-4998-BE81-2AB6385CF65DQ36014654-045B8F4A-A9B7-4EEE-BAC5-503BE2807135Q36058976-6B451444-D4FA-42F1-9BB8-EAC2629EBF4EQ36655158-7BC7625C-4D4D-4360-92F3-E1B43EBE3100Q36895403-A17B9AF7-2251-4F4C-86F4-2147C1ABE7E7Q37062084-CF5C9AE1-9DA6-4EBB-AFC7-EBD539D67A6DQ37082577-3733981C-7DE1-4096-A3AA-E00DA0E5E3A4Q37189447-DD553B06-9502-45C3-9AB1-54221682BEDEQ37591467-E5AABD4E-55BF-4598-9E92-BC6371E83BA0Q38222563-E3AC8006-DA4B-424C-9A62-70574F641C03Q38263003-65C7081B-B255-4B0F-91EB-89E186DF6B9EQ38742944-CBE352BC-C466-4FA4-8622-436EE4A13817Q38796931-F2AE21BF-5842-4180-9827-41234514E643Q38806853-4E2E9048-EF89-458F-9E06-78ADF6F4CE0CQ38817373-39100710-B9F1-4A94-97BE-763BE22B7389Q38852874-0E905AC6-AA7F-41A5-AB56-A8BDA9FF81FFQ38998531-194E0D75-A1B8-4DCE-AA97-ECDAB18593DCQ39062053-D4B2FB5A-81C5-4BF7-8A49-D563B028A8AFQ41660505-A5376FAA-10B8-4621-BB25-C909C47E7CD8Q41850633-760C8252-B613-4DCA-BEA7-78659438A7B1Q42552152-F869F435-5949-40BD-8CDB-1CE9113474CDQ47113436-1668255A-F0E5-4B40-AD70-75EF5DD87379Q47362469-6913DC1E-D825-42E6-B4C5-8642BFAA5933Q47919698-E6CABF74-3729-48CB-9553-D7892382E6A2Q49814595-BC9C28DE-2469-4D97-85D3-29AB7F25CDA1Q56476012-1B82C32E-BFAA-497A-87CC-7D59D7B7E703
P2860
A modified HSP70 inhibitor shows broad activity as an anticancer agent.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A modified HSP70 inhibitor shows broad activity as an anticancer agent.
@ast
A modified HSP70 inhibitor shows broad activity as an anticancer agent.
@en
type
label
A modified HSP70 inhibitor shows broad activity as an anticancer agent.
@ast
A modified HSP70 inhibitor shows broad activity as an anticancer agent.
@en
prefLabel
A modified HSP70 inhibitor shows broad activity as an anticancer agent.
@ast
A modified HSP70 inhibitor shows broad activity as an anticancer agent.
@en
P2093
P2860
P50
P1476
A modified HSP70 inhibitor shows broad activity as an anticancer agent.
@en
P2093
Donna L George
Gregor M Balaburski
Jessie Villanueva
Julia I-Ju Leu
Mark D Andrake
Maureen E Murphy
Neil Beeharry
Seth Hayik
P2860
P304
P356
10.1158/1541-7786.MCR-12-0547-T
P577
2013-01-09T00:00:00Z